According to a new article in the American Journal of Gastroenterology, gastroesophageal reflux disease (GRD), more commonly known as, acid reflux, is linked to obesity. Since (GRD) is strongly associated with more serious conditions, such as esophageal ulcers and cancer, weight reduction therapy may be useful in treatment and prevention of these conditions.
Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.
FDA Proposes Rules Overhaul to Expand Availability of Experimental Drugs. The Agency Also Clarifies Permissible Charges to Patients.
A natural substance made from soy appears to have amazing restorative powers when given to animals with a multiple sclerosis (MS)-like disease.
Christopher Chitambar, M.D., a physician researcher at the Medical College of Wisconsin Cancer Center in Milwaukee, has identified a compound that may be effective in treating forms of non-Hodgkin’s lymphoma (a cancer of the lymphatic system) that are resistant to certain therapies. The new agent could also offer the advantages of being administered orally, rather than intravenously, making it more convenient than intravenous agents.
For millennia anglers have wondered how fish see colors, and the rainbow of lures in every bait shop reveal that we’re still guessing. But, in fish, reptiles and birds, that’s all we can do for now, according to husband and wife vision researchers, Drs. Jay and Maureen Neitz at the Medical College of Wisconsin in Milwaukee.
A team from the Medical College of Wisconsin in Milwaukee has applied for a patent on their work to isolate, grow and identify a new and readily-available type of adult stem cell that is found in the bulge of hair follicles, and appears to have a potential for diversification similar to that of embryonic stem cells.
A monoclonal antibody developed by researchers at the University at Buffalo has been shown to extend significantly the survival of mice with human breast-cancer tumors and to inhibit the cancer’s spread to the lungs in the animals by more than 50 percent.
Researchers at the University of Texas M. D. Anderson Cancer Center reported today that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients.
Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) at this year’s American Society of Hematology (ASH) meeting.